In another study, we are considering exploring nanoparticles loaded with ApoA1 and biomimetics acceptors such as reconstituted HDL to induce cholesterol efflux and using TPEF imaging to monitor changes in the FAD-like AF signal, which would indicate improvements in cholesterol management. This evidence concerns the gene APOA1 and atrial fibrillation.